Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest
Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 777,200 shares, a growth of 182.0% from the August 31st total of 275,600 shares. Approximately 2.9% of the shares of the stock are sold short. Based on an average daily volume of 6,970,000 shares, the short-interest ratio is presently 0.1 days.
斯倍樂治療股份有限公司（NASDAQ：SPRO-獲得評級）在 9 月份短期興趣大幅增長。截至 9 月 15 日，短期利息總額達 777,200 股，較八月三十一日共 275,600 股股份增長了 182.0%。約 2.9% 股票的股份賣空。根據每日平均成交量 6,970,000 股，短息比率目前為 0.1 天。
Wall Street Analyst Weigh In
華爾街分析師稱重
Several brokerages have commented on SPRO. HC Wainwright decreased their target price on shares of Spero Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a report on Monday. Evercore ISI upgraded shares of Spero Therapeutics from an "in-line" rating to an "outperform" rating and set a $8.00 target price for the company in a report on Thursday, September 22nd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $6.33.
幾家經紀公司對 SPRO 發表了評論。溫賴特（HC Winwright）將斯倍樂治療藥物股票的目標價從 7.00 美元降至 6.00 美元，並在周一的報告中為該公司設定了「買入」評級。Evercore ISI 在 9 月 22 日（星期四）的一份報告中，將斯倍樂治療的股票從「線上」評級為「跑贏大市」評級，並為該公司設定了 8.00 美元的目標價。他們指出，這一舉動是一個估值電話。三位股票研究分析師對該股票進行了持有評級，其中兩位股票對該公司股票進行了買入評級。根據 MarketBeat 的數據，該股目前的共識評級為「持有」，共識目標價為 6.33 美元。
Insider Transactions at Spero Therapeutics
斯倍樂治療的內幕交易
In other news, major shareholder Aquilo Capital Management, Llc sold 1,901,796 shares of Spero Therapeutics stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $2.25, for a total value of $4,279,041.00. Following the transaction, the insider now owns 3,419,435 shares of the company's stock, valued at approximately $7,693,728.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.36% of the company's stock.
在其他消息中，主要股東阿奎洛資本管理有限公司在 9 月 22 日（星期四）發生的一項交易中出售了斯倍樂治療股票的 1,901,796 股。這些股票以 2.25 美元的平均價格出售，總價值為 4,279,041 美元。交易完成後，內幕人士現在擁有該公司股票 3,419,435 股，價值約為 7,693,728.75 美元。出售在與證券交易委員會的文件中披露，該文件可通過以下方式訪問 證券交易所網站。企業內部人士擁有公司股票的 4.36％。
Hedge Funds Weigh In On Spero Therapeutics
對沖基金權衡斯倍樂治療
Spero Therapeutics Price Performance
斯倍樂治療價格性能
SPRO traded down $0.07 during midday trading on Tuesday, hitting $2.02. 9,774,324 shares of the company's stock traded hands, compared to its average volume of 2,793,390. The company has a market cap of $70.84 million, a PE ratio of -0.58 and a beta of 1.87. The stock's fifty day simple moving average is $0.98 and its 200-day simple moving average is $2.61. Spero Therapeutics has a one year low of $0.68 and a one year high of $19.87.
SPRO 週二中午交易時間下跌 0.07 美元，觸及 2.02 美元。該公司股票交易手中的 9,774,324 股，而該公司股票的平均交易量為 2,793,390。該公司的市值為 70.84 萬美元，私募股權比率為 -0.58，測試版為 1.87。該股的五十天簡單移動平均線為 0.98 美元，其 200 天的簡單移動平均線為 2.61 美元。斯倍樂治療有一年低點 0.68 美元和一年的高點 19.87 美元。
Spero Therapeutics Company Profile
斯倍樂治療公司簡介
(Get Rating)
(取得評分)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
斯倍樂治療, Inc. 是一家臨床階段生物製藥公司，致力於在美國識別、開發和商業化多重抗藥性 (MDR) 細菌感染和罕見疾病的治療方法。該公司的候選產品包括氫溴化替培南（HBR），一種用於治療複雜性尿路感染的口服碳青黴素類抗生素，包括成人腎盂腎炎；SPR206，一種直接代理 IV 給藥劑，用於治療醫院的 MDR 革蘭氏陰性細菌感染；以及用於治療非結核肺病的口服抗生素 SPR720。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
- Build A Better Tech Portfolio With Jabil Inc.
- Autodesk Is A Mature Company Still Acting Like A Growth Stock
- Is There Value In These Growth Stocks?
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Is the Market Overreacting with Shopify Stock?
- 免費獲得斯倍樂治療研究報告
- 與捷普建立更好的技術產品組合
- 歐特克是一家成熟的公司，仍然像成長股一樣行事
- 這些增長股票有價值嗎？
- 市場節拍播客, 3 個股票觀看紐蒙特礦業, 沃爾瑪, AMC
- 市場對 Shopify 股票的反應過度嗎？
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收斯倍樂治療日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收斯倍樂治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。